Wednesday, November 19, 2025 11:32:47 PM
The problem with the reverse split is the downward journey is swift. By staying on the current path, they can at least prevent that to some extent and also prevent a mass exodus of existing shareholders.
Either way, the company has no real future except endless dilution in pennies at increasingly lower share price.
The fact that they are talking about moving on to Direct trials coupled with all the delays in MHRA review of L pretty much indicates that L is likely going to be rejected. Otherwise, why wouldn’t you want to run new trials with L in other indications when it is about to get approval in GBM. Also, why wouldn’t you spend resources on commercializing L in GBM indication in UK & US rather than spending those scarce resources and money on new trials with Direct. Makes no sense.
It seems they knew L was going to get rejected and the submission in the UK was merely a hail mary pass to keep shareholders engaged for an year or two while their buddies cash out and they work on logistics for a new Direct trial.
Either way, the company has no real future except endless dilution in pennies at increasingly lower share price.
The fact that they are talking about moving on to Direct trials coupled with all the delays in MHRA review of L pretty much indicates that L is likely going to be rejected. Otherwise, why wouldn’t you want to run new trials with L in other indications when it is about to get approval in GBM. Also, why wouldn’t you spend resources on commercializing L in GBM indication in UK & US rather than spending those scarce resources and money on new trials with Direct. Makes no sense.
It seems they knew L was going to get rejected and the submission in the UK was merely a hail mary pass to keep shareholders engaged for an year or two while their buddies cash out and they work on logistics for a new Direct trial.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
